Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	20.95	-72.7	-135.35	-108.5	-73.96	-35.88
Depreciation & Amortization	10.67	10.22	8.32	3.75	2.13	0.54
Loss (Gain) From Sale of Assets	-0.06	-	-0.02	-0.11	0.02	-
Loss (Gain) From Sale of Investments	-2.93	-2.95	-3.78	-1.95	-	-
Stock-Based Compensation	19.03	18.13	16.67	11.66	5.2	0.35
Other Operating Activities	-2.34	-2.1	-2.1	4.81	0.96	7.68
Change in Accounts Receivable	-4.37	0.33	1.9	-0.19	-	-
Change in Accounts Payable	10.21	6.25	5.76	-0.74	-0.71	3.44
Change in Unearned Revenue	92.66	83.38	50	-	-	-
Change in Other Net Operating Assets	5.32	1.44	14.81	-1.2	6.99	0.82
Operating Cash Flow	149.14	42	-43.8	-92.47	-59.36	-23.05
Capital Expenditures	-4.12	-3.99	-19.04	-12.91	-9.73	-3.39
Sale of Property, Plant & Equipment	-	-	0.06	0.11	0.08	-
Investment in Securities	-63.55	-40.46	107.78	-206.42	-	-
Investing Cash Flow	-67.66	-44.45	88.8	-219.22	-9.65	-3.39
Issuance of Common Stock	1.34	52.53	2.61	21.45	255.79	-
Other Financing Activities	-	46.36	24.88	-0.98	-21.23	-0.44
Financing Cash Flow	1.34	98.89	27.49	20.47	377.56	60.06
Net Cash Flow	82.81	96.44	72.49	-291.22	308.55	33.62
Free Cash Flow	145.02	38.01	-62.84	-105.38	-69.1	-26.44
Free Cash Flow Margin	79.88%	50.26%	-	-	-	-
Free Cash Flow Per Share	1.75	0.51	-1.22	-2.23	-2.76	-17.43
Levered Free Cash Flow	48.56	81.97	-53.37	-72.4	-61.29	7.6
Unlevered Free Cash Flow	48.56	81.97	-53.37	-72.4	-61.29	7.6
Change in Working Capital	103.83	91.4	72.47	-2.13	6.29	4.26

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q